Ahmed Mohamed H, Raza Mansoor, Lucas Sebastian, Mital Dushyant
Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keyne, Buckinghamshire, London, UK.
Department of Infectious Diseases and Microbiology, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keyne, Buckinghamshire, London, UK.
J Microsc Ultrastruct. 2020 Nov 9;9(1):41-44. doi: 10.4103/JMAU.JMAU_16_20. eCollection 2021 Jan-Mar.
We report a case of a 46-year-old female living with HIV since 2010 who was originally from Malawi and had settled in the UK in 2001. She was admitted to our hospital with confusion and quickly noted to have a decreased Glasgow Coma Scale of 10/15. Her biochemical parameters showed the presence of elevated liver function tests (LFTs), clotting abnormalities, and her ammonia were found to be >400 mmol/L with a severe metabolic acidosis (pH = 7.05). She was treated for HIV with combined antiretroviral therapy, namely tenofovir disoproxil fumarate, emtricitabine (FTC) and cobicistat boosted atazanavir 2 years previously and had normal LFTs at that time. Her HIV-1 viral load was 1400 copies/ml on admission after recently having an undetectable viral load 2 months previously, and her CD4 count was 480. Her relevant past medical history included insulin-dependent diabetes mellitus. Her other medications included insulin, ramipril, sertraline, amitriptyline, and zopiclone. Toxicology and viral hepatitis screen were negative. Epstein Barr virus (EBV) serology showed evidence of previous exposure, but she was found to have a very high EBV viral load of 55,000 copies/ml, which given her serology, was very likely to be a reactivation of EBV infection rather than a primary EBV infection. In the intensive care unit, the patient deteriorated and died very quickly. The postmortem examination showed extensive hepatic necrosis with collapse. To our knowledge, this is the first case report to show an association between EBV reactivation and fulminant hepatic failure in an individual living with HIV.
我们报告一例自2010年起感染艾滋病毒的46岁女性病例,她原籍马拉维,于2001年定居英国。她因意识模糊入院,很快发现格拉斯哥昏迷量表评分降至10/15。她的生化指标显示肝功能检查(LFTs)升高、凝血异常,且氨水平>400 mmol/L,伴有严重代谢性酸中毒(pH = 7.05)。她在两年前开始接受抗逆转录病毒联合治疗,即替诺福韦酯、恩曲他滨(FTC)和考比司他增强的阿扎那韦治疗,当时肝功能检查正常。入院时她的HIV-1病毒载量为1400拷贝/ml,而两个月前病毒载量还检测不到,她的CD4细胞计数为480。她的相关既往病史包括胰岛素依赖型糖尿病。她的其他药物包括胰岛素、雷米普利、舍曲林、阿米替林和佐匹克隆。毒理学和病毒性肝炎筛查均为阴性。爱泼斯坦-巴尔病毒(EBV)血清学显示有既往感染证据,但发现她的EBV病毒载量非常高,为55,000拷贝/ml,鉴于其血清学情况,很可能是EBV感染的重新激活而非原发性EBV感染。在重症监护病房,患者病情恶化并很快死亡。尸检显示广泛的肝坏死并伴有肝组织塌陷。据我们所知,这是首例显示EBV重新激活与艾滋病毒感染者暴发性肝衰竭之间存在关联的病例报告。